Literature DB >> 26235192

In-hospital worsening heart failure.

Javed Butler1, Mihai Gheorghiade2, Anita Kelkar3, Gregg C Fonarow4, Stefan Anker5, Stephen J Greene2, Lampros Papadimitriou1, Sean Collins6, Frank Ruschitzka7, Clyde W Yancy2, John R Teerlink8, Kirkwood Adams9, Gadi Cotter10, Piotr Ponikowski11, G Michael Felker12, Marco Metra13, Gerasimos Filippatos14.   

Abstract

Acute worsening heart failure (WHF) is seen in a sizable portion of patients hospitalized for heart failure, and is increasingly being recognized as an entity that is associated with an adverse in-hospital course. WHF is generally defined as worsening heart failure symptoms and signs requiring an intensification of therapy, and is reported to be seen in anywhere from 5% to 42% of heart failure admissions. It is difficult to ascertain the exact epidemiology of WHF due to varying definitions used in the literature. Studies indicate that WHF cannot be precisely predicted on the basis of baseline variables assessed at the time of admission. Recent data suggest that some experimental therapies may reduce the risk of development of WHF among hospitalized heart failure patients, and this is associated with a reduction in risk of subsequent post-discharge cardiovascular mortality. In this respect, WHF holds promise as a endpoint for acute heart failure clinical trials to better elucidate the benefit of targeted novel therapies. Better understanding of the pathophysiology and a consensus on the definition of WHF will further improve our epidemiological and clinical understanding of this entity.
© 2015 The Authors European Journal of Heart Failure © 2015 European Society of Cardiology.

Entities:  

Keywords:  Acute heart failure; Worsening heart failure

Mesh:

Year:  2015        PMID: 26235192     DOI: 10.1002/ejhf.333

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  16 in total

Review 1.  Drugs' development in acute heart failure: what went wrong?

Authors:  Vincenzo Teneggi; Nithy Sivakumar; Deborah Chen; Alex Matter
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

Review 2.  Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction.

Authors:  John W Ostrominski; Muthiah Vaduganathan
Journal:  Clin Cardiol       Date:  2022-06       Impact factor: 3.287

3.  Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.

Authors:  Javed Butler; Adrian F Hernandez; Kevin J Anstrom; Andreas Kalogeropoulos; Margaret M Redfield; Marvin A Konstam; W H Wilson Tang; G Michael Felker; Monica R Shah; Eugene Braunwald
Journal:  JACC Heart Fail       Date:  2016-08-10       Impact factor: 12.035

Review 4.  Stem cell therapy for heart failure: Ensuring regenerative proficiency.

Authors:  Andre Terzic; Atta Behfar
Journal:  Trends Cardiovasc Med       Date:  2016-01-28       Impact factor: 6.677

5.  Implications of Using Different Definitions on Outcomes in Worsening Heart Failure.

Authors:  Jacob P Kelly; Lauren B Cooper; Dianne Gallup; Kevin J Anstrom; Horng H Chen; Margaret M Redfield; Christopher M O'Connor; Robert J Mentz; Adrian F Hernanadez; G Michael Felker
Journal:  Circ Heart Fail       Date:  2016-08       Impact factor: 8.790

6.  Association between Respiratory Failure and Clinical Outcomes in Patients with Acute Heart Failure: Analysis of 5 Pooled Clinical Trials.

Authors:  P Elliott Miller; Sean Van Diepen; Thomas S Metkus; Carlos L Alviar; Erin Rayner-Hartley; Sarah Rathwell; Jason N Katz; Justin Ezekowitz; Nihar R Desai; Tariq Ahmad
Journal:  J Card Fail       Date:  2021-02-05       Impact factor: 5.712

7.  Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.

Authors:  John R Teerlink; Adriaan A Voors; Piotr Ponikowski; Peter S Pang; Barry H Greenberg; Gerasimos Filippatos; G Michael Felker; Beth A Davison; Gad Cotter; Claudio Gimpelewicz; Leandro Boer-Martins; Margaret Wernsing; Tsushung A Hua; Thomas Severin; Marco Metra
Journal:  Eur J Heart Fail       Date:  2017-04-28       Impact factor: 15.534

Review 8.  Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions.

Authors:  Lars H Lund; Jonas Oldgren; Stefan James
Journal:  Curr Heart Fail Rep       Date:  2017-04

Review 9.  Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular-only pacing.

Authors:  Gerasimos Filippatos; David Birnie; Michael R Gold; Bart Gerritse; Ahmad Hersi; Sandra Jacobs; Kengo Kusano; Christophe Leclercq; Wilfried Mullens; Bruce L Wilkoff
Journal:  Eur J Heart Fail       Date:  2017-07       Impact factor: 15.534

10.  Clinical development plan for regenerative therapy in heart failure.

Authors:  Andre Terzic; Atta Behfar; Gerasimos Filippatos
Journal:  Eur J Heart Fail       Date:  2016-01-21       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.